BFM
CTMX icon

Boothbay Fund Management’s CytomX Therapeutics CTMX Stock Holding History

Boothbay Fund Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-626
Closed -$1.16M – 701
2018
Q3 		$1.16M Buy
626
+228
+57% +$5.2K 0.11% 173
2018
Q2 		$910K Buy
+398
New +$10.2K 0.08% 206

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Boothbay Fund Management's CTMX Position: Q2 2026 in Review

Boothbay Fund Management held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 15,000 shares worth $56.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2092.

Boothbay Fund Management first reported a position in CTMX in Q4 2018 and has held it in 11 quarters since. The position peaked at $3.95M in Q3 2025. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Boothbay Fund Management held 15,000 shares of CytomX Therapeutics worth $56.3K as of Q2 2026.
  • Boothbay Fund Management left its CytomX Therapeutics share count unchanged in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2092 holding.
  • Boothbay Fund Management first reported a position in CytomX Therapeutics in Q4 2018 and has held it in 11 quarters since.
  • Boothbay Fund Management's CytomX Therapeutics position peaked at $3.95M in Q3 2025.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.